James Byrne, MD, PhD, of University of Iowa Health Care, is doing highly innovative research to improve patient outcomes. The NIH is noticing.

Researchers found that a protein made by tiny creatures called tardigrades can protect mouse and human cells from radiation damage. The findings hold promise for reducing the harmful side effects of radiation therapy to treat cancer.

Humans undergoing similar radiation for cancer treatment often suffer painful side effects

Researchers at University of Iowa Health Care, MIT, and Brigham and Women’s Hospital, are creating a unique approach to protect healthy tissue during radiation therapy.

How does drug resistance to targeted therapy occur?

Sixteen pumpkins on display in the Rad Onc lobby leading up to Halloween.

Iowa researchers explore gas-entrapping materials to boost chemotherapy, radiation treatments.

James Byrne, MD, PhD, assistant professor of radiation oncology at University of Iowa Health Care, has been awarded the prestigious 2024 NIH Director’s New Innovator Award, recognizing his groundbreaking work aimed at improving outcomes and quality of life for cancer patients undergoing radiation therapy. Byrne is one of 40 early career scientists across the nation to receive this award, which is part of the NIH Common Fund's High-Risk, High-Reward Research Program that supports exceptionally innovative research projects led by early career investigators.

A paper authored by Dr. Byrne has earned a place on the College of Medicine's Wall of Scholarship.

Richard Hakes, features the decorated face masks made for pediatric patients based on his experience as a H&N cancer patient.

An article published in Frontiers in Oncology discusses ways of reducing tumor motion for the treatment of pancreatic tumors.

Surrogate gating strategies used to treat moving targets.